Literature DB >> 1695407

Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients.

I Bodis-Wollner1.   

Abstract

In patients affected by Parkinson's disease, and in the monkey model of this disease, visual defects have been shown using psychophysical and electrophysiological measures of spatial and temporal contrast sensitivity. These studies imply an essential role for dopamine in primate vision. There is electrophysiological and neurochemical evidence to suggest that at least part of the problem is impaired retinal processing caused by systemic dopaminergic deficiency. Some of the deficits that have been demonstrated, consistent with physiological studies, suggest that center-surround interaction of neurons may suffer as a consequence of dopaminergic deficiency. The role of the regulation of retinal dopamine (D1 and D2) receptors in primate vision and of the balance of these receptors in presynaptic dopaminergic deficiency is not yet determined. Using sinusoidal grating stimuli in cognitively loaded tasks may increase understanding of the behavioral consequences of visual deficits seen in dopamine deficiency syndromes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1695407     DOI: 10.1016/0166-2236(90)90113-o

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  59 in total

1.  Effects of dopamine depletion on visual sensitivity of zebrafish.

Authors:  L Li; J E Dowling
Journal:  J Neurosci       Date:  2000-03-01       Impact factor: 6.167

2.  Correlation between retinal morphological and functional findings and clinical severity in Parkinson's disease.

Authors:  Ozgül Altintaş; Pervin Işeri; Berna Ozkan; Yusuf Cağlar
Journal:  Doc Ophthalmol       Date:  2007-10-26       Impact factor: 2.379

3.  Relation of Parkinson's disease subtypes to visual activities of daily living.

Authors:  Daniel R Seichepine; Sandy Neargarder; Ivy N Miller; Tatiana M Riedel; Grover C Gilmore; Alice Cronin-Golomb
Journal:  J Int Neuropsychol Soc       Date:  2011-08-04       Impact factor: 2.892

4.  From Imaging the Brain to Imaging the Retina: Optical Coherence Tomography (OCT) in Schizophrenia.

Authors:  Carlos Schönfeldt-Lecuona; Thomas Kregel; Arno Schmidt; Elmar H Pinkhardt; Florian Lauda; Jan Kassubek; Bernhard J Connemann; Roland W Freudenmann; Maximilian Gahr
Journal:  Schizophr Bull       Date:  2015-06-05       Impact factor: 9.306

5.  Simultaneously evoked primary and cognitive visual evoked potentials distinguish younger and older patients with Parkinson's disease.

Authors:  A Antal; R Pfeiffer; I Bodis-Wollner
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

6.  Visual hallucinosis: the major clinical determinant of distorted chromatic contour perception in Parkinson's disease.

Authors:  T Büttner; W Kuhn; T Müller; F L Welter; J Federlein; K Heidbrink; H Przuntek
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

7.  'Gamma' band oscillatory response to chromatic stimuli in volunteers and patients with idiopathic Parkinson's disease.

Authors:  Walter G Sannita; Simone Carozzo; Paolo Orsini; Luciano Domenici; Vittorio Porciatti; Mauro Fioretto; Sergio Garbarino; Ferdinando Sartucci
Journal:  Vision Res       Date:  2009-02-14       Impact factor: 1.886

Review 8.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

9.  The multicomponent nature of equilibrium in persons with parkinsonism: a regression approach.

Authors:  T Toole; S Park; M A Hirsch; D A Lehman; C G Maitland
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

10.  Subclinical visual impairment in phenylketonuria. A neurophysiological study (VEP-P) with clinical, biochemical, and neuroradiological (MRI) correlations.

Authors:  V Leuzzi; S Rinalduzzi; F Chiarotti; P Garzia; G Trasimeni; N Accornero
Journal:  J Inherit Metab Dis       Date:  1998-06       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.